biostudies-literatureSethi SEuropean Research CouncilNCI NIH HHS1123-1136https://www.ebi.ac.uk/biostudies/studies/S-EPMC6551791biostudies-literatureUnknown30(6)<h4>Background</h4>In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively. In other cases of primary MN and in secondary MN, the target antigens are unknown.<h4>Methods</h4>We studied 224 cases of biopsy-proven PLA2R-negative MN and 102 controls (including 47 cases of PLA2R-associated MN) in pilot and discovery cohorts. We also evaluated 48 cases of PLA2R-negative presumed primary MN and lupus MN in a validation cohort. We used laser microdissection and mass spectrometry to identify new antigens, which were localized by immunohistochemistry.<h4>Journal of the American Society of Nephrology : JASNExostosin 1/Exostosin 2-Associated Membranous Nephropathy.PMC6551791322947P30 CA015083Specks USethi SGross LMadden BJRonco PDebiec HCharlesworth MCRavindran AHummel AMFervenza FCfalseExostosin 1/Exostosin 2-Associated Membranous Nephropathy.<h4>Background</h4>In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively. In other cases of primary MN and in secondary MN, the target antigens are unknown.<h4>Methods</h4>We studied 224 cases of biopsy-proven PLA2R-negative MN and 102 controls (including 47 cases of PLA2R-associated MN) in pilot and discovery cohorts. We also evaluated 48 cases of PLA2R-negative presumed primary MN and lupus MN in a validation cohort. We used laser microdissection and mass spectrometry to identify new antigens, which were localized by immunohistochemistry.<h4>2019-01-01T00:00:00Z2019 Jun2025-04-04T07:57:42.484Z2025-04-04T07:57:42.484ZS-EPMC65517913106113910.1681/asn.201808085210.1681/ASN.2018080852